40. De Paula AL, Stival AR, Macedo A, et al. Randomized
controlled trial comparing 2 versions of laparoscopic ileal
interposition associated with sleeve gastrectomy for patients
with type 2 diabetes with BMI 21–34 kg/m2. Surg Obes Relat
Dis. 2010; 6( 3):296-304.
41. Payab M, Hasani-Ranjibar SH. Ileal interposition surgery
for treatment of type 2 diabetes mellitus—pros and cons.
J Diabetes Metab Disord. 2015; 14( 1): 17.
42. Talebpour M, Motamedi SM, Talebpour A, Vahidi H.
Twelve year experience of laparoscopic gastric plication in
morbid obesity: Development of the technique and patient
outcomes. Ann Surg Innov Res. 2012; 6( 1): 7.
43. Fried M, Dolezalova K, Buchwald JN, McGlennon T W,
Sramkova P, Ribaric G. Laparoscopic greater curvature
plication (LGCP) for treatment of morbid obesity in a series
of 244 patients. Obes Surg. 2012; 22( 8):1298-1307.
44. Abdelbaki TN, Huang CK, Ramos A, Neto MG, Talebpour M,
Saber AA. Gastric plication for morbid obesity: A systematic
review. Obes Surg. 2012; 22( 10):1633-1639.
45. Huang CK, Chhabra N, Goel R, Hung CM, Chang PC,
Chen YS. Laparoscopic adjustable gastric banded plication:
A case-matched comparative study with laparoscopic sleeve
gastrectomy. Obes Surg. 2013; 23( 8):1319-1323.
46. Patel SR, Hakim D, Mason J, Hakim N. The duodenal-jejunal
bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight
loss and treatment of type 2 diabetes. Surg Obes Relat Dis.
2013; 9( 3):482-484.
47. Escalona A, Pimentel F, Sharp A, et al. Weight loss and
metabolic improvement in morbidly obese subjects
implanted for 1 year with an endoscopic duodenal-jejunal
bypass liner. Ann Surg. 2012;255( 6):1080-1085.
48. Rohde U, Hedback N, Gluud LL, Vilsboll T, Knop FK. Effects
of the EndoBarrier Gastrointestinal Liner on obesity and
type 2 diabetes: A systematic review and meta-analysis.
Diabetes Obes Metab. 2016; 18( 3):300-305.
49. World Medical Association. WMA Declaration of Helsinki—
Ethical Principles for Medical Research Involving Human
Subjects. July 9, 2018. Fortaleza, Brazil. Available at: www.
Accessed February 12, 2019.
50. Skierka AS, Michels KB. Ethical principles and placebo-controlled trials—interpretation and implementation of
the Declaration of Helsinki’s placebo paragraph in medical
research. BMC Med Ethics. 2018; 19( 1): 24.
respected set of ethical principles used to guide
medical researchers in protecting patients enrolled
in biomedical trials. The declaration opposes the
ethics of placebo-controlled trials as purposefully
withholding treatment from some individuals.49
However, countries such as the U.S., Canada, Australia, and Japan use the Declaration of Helsinki, as
well as other ethical guides, and still use placebo-controlled trials. 50 ♦
This work was supported by the ACS. The authors
declare that they have no relevant conflict of interest.
Dr. Fobi declares that he is founding president and a
shareholder of Bariatec Corporation (manufacturer of
the ring devices). Dr. Fobi also discloses that he was a
recipient of the ring banded gastric bypass in 2011 to
Dr. Gagner declares speaker honoraria from Ethi-con, Medtronic, Valeant, and Gore; and stock options
We are grateful to the ACS for their generous sponsorship of the Metabolic Surgery Symposium and
associated journal publication development. We thank
Jane N. Buchwald, chief scientific research writer, Medwrite Medical Communications, Maiden Rock, WI,
for manuscript editing and publication coordination.
And we thank Patrick Beebe and Donna Coulombe,
ACS Executive Services, for their expert organization
of the Metabolic Surgery Symposium.